MHRA approves tecovirimat to prevent smallpox, monkeypox, cowpox, and vaccinia complications.
SIGA Technologies, Inc. announced that the United Kingdom has approved SIGA’s oral tecovirimat (known in the U.S. as oral TPOXX) for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox in adults and children with a body weight of at least 13kg.
The same formulation of tecovirimat was approved by the FDA in 2018 and by Health Canada in late 2021 under the brand name TPOXX for the treatment of smallpox. In early 2022 SIGA also received market authorization for tecovirimat from the European Medicines Agency for the treatment of smallpox, monkeypox, cowpox, and complications from vaccinia infection.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.